当前位置: 首页 >> 检索结果
4183. Human Gut Microbiota and Its Metabolites Impact Immune Responses in COVID-19 and Its Complications.
作者: Naoyoshi Nagata.;Tadashi Takeuchi.;Hiroaki Masuoka.;Ryo Aoki.;Masahiro Ishikane.;Noriko Iwamoto.;Masaya Sugiyama.;Wataru Suda.;Yumiko Nakanishi.;Junko Terada-Hirashima.;Moto Kimura.;Tomohiko Nishijima.;Hiroshi Inooka.;Tohru Miyoshi-Akiyama.;Yasushi Kojima.;Chikako Shimokawa.;Hajime Hisaeda.;Fen Zhang.;Yun Kit Yeoh.;Siew C Ng.;Naomi Uemura.;Takao Itoi.;Masashi Mizokami.;Takashi Kawai.;Haruhito Sugiyama.;Norio Ohmagari.;Hiroshi Ohno.
来源: Gastroenterology. 2023年164卷2期272-288页
We investigate interrelationships between gut microbes, metabolites, and cytokines that characterize COVID-19 and its complications, and we validate the results with follow-up, the Japanese 4D (Disease, Drug, Diet, Daily Life) microbiome cohort, and non-Japanese data sets.
4190. Comparison of the value of conventional two-dimensional ultrasound, contrast-enhanced ultrasound and MSCT in early diagnosis of small hepatocellular carcinoma.
作者: Fei Xie.;Yongqiang Hong.;Xixi Sun.;Boyi Wang.;Qingxiang Meng.;Jie Guo.;Bin Huang.
来源: Minerva Gastroenterol (Torino). 2023年69卷1期162-165页 4192. Effects of mosapride combined with rabeprazole on symptom scores and inflammatory factors in elderly patients with reflux esophagitis.
作者: Chaoliang Mao.;Xiaole Wu.;Zijuan Pu.;Delin Chen.;Yushun Pu.;Aici Peng.
来源: Minerva Gastroenterol (Torino). 2023年69卷1期149-151页 4193. Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir.
作者: Grace Lai-Hung Wong.;Vicki Wing-Ki Hui.;Terry Cheuk-Fung Yip.;Grace Chung-Yan Lui.;David Shu-Cheong Hui.;Vincent Wai-Sun Wong.
来源: Gastroenterology. 2023年164卷1期151-153页 4195. Th17 Cell-Derived Amphiregulin Promotes Colitis-Associated Intestinal Fibrosis Through Activation of mTOR and MEK in Intestinal Myofibroblasts.
作者: Xiaojing Zhao.;Wenjing Yang.;Tianming Yu.;Yu Yu.;Xiufang Cui.;Zheng Zhou.;Hui Yang.;Yanbo Yu.;Anthony J Bilotta.;Suxia Yao.;Jimin Xu.;Jia Zhou.;Gregory S Yochum.;Walter A Koltun.;Austin Portolese.;Defu Zeng.;Jingwu Xie.;Iryna V Pinchuk.;Hongjie Zhang.;Yingzi Cong.
来源: Gastroenterology. 2023年164卷1期89-102页
Intestinal fibrosis is a significant complication of Crohn's disease (CD). Gut microbiota reactive Th17 cells are crucial in the pathogenesis of CD; however, how Th17 cells induce intestinal fibrosis is still not completely understood.
4196. Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma.
作者: Philipp K Haber.;Florian Castet.;Miguel Torres-Martin.;Carmen Andreu-Oller.;Marc Puigvehí.;Maeda Miho.;Pompilia Radu.;Jean-Francois Dufour.;Chris Verslype.;Carolin Zimpel.;Jens U Marquardt.;Peter R Galle.;Arndt Vogel.;Melanie Bathon.;Tim Meyer.;Ismail Labgaa.;Antonia Digklia.;Lewis R Roberts.;Mohamed A Mohamed Ali.;Beatriz Mínguez.;Davide Citterio.;Vincenzo Mazzaferro.;Fabian Finkelmeier.;Jörg Trojan.;Burcin Özdirik.;Tobias Müller.;Moritz Schmelzle.;Anthony Bejjani.;Max W Sung.;Myron E Schwartz.;Richard S Finn.;Swan Thung.;Augusto Villanueva.;Daniela Sia.;Josep M Llovet.
来源: Gastroenterology. 2023年164卷1期72-88.e18页
Single-agent anti-PD1 checkpoint inhibitors convey outstanding clinical benefits in a small fraction (∼20%) of patients with advanced hepatocellular carcinoma (aHCC) but the molecular mechanisms determining response are unknown. To fill this gap, we herein analyze the molecular and immune traits of aHCC in patients treated with anti-PD1.
|